title: Palladium-103 radiation therapy for small choroidal melanoma.
abstract: OBJECTIVE
  To evaluate outcomes after ophthalmic plaque radiation therapy for small choroidal melanomas.
  
  
  METHODS
  Retrospective study, case series.
  
  
  METHODS
  Seventy-two patients with choroidal melanomas ≥1.5 and ≤2.4 mm apical height and ≤10 mm width treated between 2002 and 2012, with a minimum follow-up of 8 months.
  
  
  METHODS
  All patients were treated with palladium-103 plaque brachytherapy. Mean radiation dose to the tumor apex was 82.4 Gy (range, 70.0-102 Gy).
  
  
  METHODS
  Local control, radiation complications, visual acuity, and metastatic rate.
  
  
  RESULTS
  Plaque radiotherapy provided 100% local tumor control and eye retention at a mean 54 months of observation (95% confidence interval, 46-63 months). The most common long-term brachytherapy-related complications were radiation maculopathy (43.1%) and radiation optic neuropathy (20.8%) developing at a mean of 27 months (range, 9-72 months) after irradiation. In this series, 94.4% of patients maintained 20/200 or better vision. There has been no small choroidal melanoma-related metastasis.
  
  
  CONCLUSIONS
  Palladium-103 plaque radiation therapy offered excellent local control and visual acuity outcomes for patients with small choroidal melanoma.
authors.affiliation: The New York Eye Cancer Center, New York, New York; The New York Eye and Ear Infirmary, New York, New York.
authors.forename: Ekaterina
authors.initials: E
authors.lastname: Semenova
authors.forename: Paul T
authors.initials: PT
authors.lastname: Finger
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy; D002830:Choroid Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008545:Melanoma / Q000473:pathology / Q000532:radiotherapy*; D008875:Middle Aged; D009367:Neoplasm Staging; D010165:Palladium / Q000009:adverse effects / Q000627:therapeutic use*; D011868:Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology; D055815:Young Adult
chemical_list: D011868:Radioisotopes; D010165:Palladium